Caribou Biosciences, Inc. (CRBU) Stock Grade

About Caribou Biosciences, Inc.'s fundamentals

Caribou Biosciences is a biotechnology company with a market capitalization of $148.5 million that reported revenue growth of 11.7% year-over-year, indicating expansion in its top line. However, the company operates at a significant loss with a net margin of -1327.4%, reflecting the substantial expenses typical of early-stage biotech firms developing new treatments. The company does not pay a dividend and reported a net loss in its latest annual statement, which is common for pre-profitability biotechnology companies investing heavily in research and development.